Neuren Pharmaceuticals Limited (NEU.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 420.83k | -- | -- |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | -- | -- | -- |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | -- | -- | -- |
| Mr. Gerry Zhao | Vice President of Corporate Development | -- | -- | -- |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | -- | -- | -- |
Neuren Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Corporate Governance
Recent Events
Recent Events Information Not Available